Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 185 |
| Active Pipeline (Recruiting Now) | 54 (43) |
| Completed vs Stopped Early | 99 / 32 (17.3%) |
| Median Closed Actual Enrollment | 94 participants |
| Physical Hospital Site Disclosure | 97.7% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| UCLA Health and Jonsson Comprehensive Cancer Center | Los Angeles, CA | 41 |
| UCSF Medical Center and Helen Diller Cancer Center | San Francisco, CA | 40 |
| Vanderbilt University Medical Center | Nashville, TN | 38 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07015996 | Efficacy of Tezepelumab in Peanut Oral Immunotherapy | Phase II | RECRUITING |
| NCT06075745 | Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates | Phase II | RECRUITING |
| NCT06476132 | Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients | Phase II | RECRUITING |
| NCT05201469 | VIBRANT: VIB4920 for Active Lupus Nephritis | Phase II | RECRUITING |
| NCT06280950 | Expanding Liver Transplant Immunosuppression Minimization Via Everolimus | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the National Institute of Allergy and Infectious Diseases (NIAID) Interactive Dossier, benchmark peers in Infectious Disease and Vaccines, or review the Healthcare Price & Patent Cliff Crosswalk.